Related Experiment Videos
[Bone fracture receiving LH-RH agonists for prostatic cancer]
T Hatano1, H Igarashi, J Nakada
1Department of Urology, Jikei University School of Medicine.
Summary
Luteinizing hormone-releasing hormone (LHRH) agonists used for prostate cancer can lead to osteoporosis and fractures due to low testosterone. Bone density and metabolic markers, particularly NTx, were significantly altered in patients who fractured.
Area of Science:
- Endocrinology
- Oncology
- Bone Metabolism
Context:
- Luteinizing hormone-releasing hormone (LHRH) agonists are standard treatment for prostate cancer.
- Long-term use can cause hypogonadism, leading to reduced bone mineral density and osteoporosis.
- Osteoporosis is a significant risk factor for fractures in elderly patients.
Purpose:
- To investigate bone mineral density and bone metabolic markers in prostate cancer patients treated with LHRH agonists who experienced fractures.
- To identify potential indicators of fracture risk in this patient population.
Summary:
- This study compared bone density and metabolic markers in 13 prostate cancer patients who fractured while on LHRH agonists versus 70 controls.
- Fractured patients exhibited significantly lower bone density at the third lumbar vertebra.
- Elevated urinary type 1 collagen cross-linked N-telopeptides (NTx) were observed in the fracture group, indicating increased bone resorption.
Impact:
- Highlights the risk of secondary osteoporosis and fractures associated with LHRH agonist therapy for prostate cancer.
- Suggests periodic monitoring of bone mineral density and bone metabolic markers is crucial.
- Emphasizes the need for early evaluation and management of osteoporosis in these patients.